Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.
We have exploited the polyamine transport system (PTS) to deliver selectively a spermine-drug conjugate, F14512 to cancer cells. This study was aimed to define F14512 anticancer efficacy against tumor models and to investigate whether fluorophor-labeled polyamine probes could be used to identify tumors expressing a highly active PTS and that might be sensitive to F14512 treatments. Eighteen tumor models were used to assess F14512 antitumor activity. Cellular uptake of spermine-based fluorescent probes was measured by flow cytometry in cells sampled from tumor xenografts by needle biopsy. The accumulation of the fluorescent probe within B16 tumors in vivo was assessed using infrared fluorescence imaging. This study has provided evidence of a major antitumor activity for F14512. Significant responses were obtained in 67% of the tumor models evaluated, with a high level of activity recorded in 33% of the responsive models. Complete tumor regressions were observed after i.v., i.p. or oral administrations of F14512 and its antitumor activity was demonstrated over a range of 2-5 dose levels, providing evidence of its good tolerance. The level of cellular fluorescence emitted by the fluorescent probes was higher in cells sampled from tumors sensitive to F14512 treatments than from F14512-refractory tumors. We suggest that these probes could be used to identify tumors expressing a highly active PTS and guide the selection of patients that might be treated with F14512. These results emphasize the preclinical interest of this novel molecule and support its further clinical development.
Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Parc Technologique du Canal, 3 rue des Satellites, B.P. 94244, 31432, Toulouse Cedex 04, France. anna.kruczynski@pierre-fabre.com
Anna
A
Kruczynski
Isabelle
I
Vandenberghe
Arnaud
A
Pillon
Sabrina
S
Pesnel
Liliane
L
Goetsch
Jean-Marc
JM
Barret
Yves
Y
Guminski
Alain
A
Le Pape
Thierry
T
Imbert
Christian
C
Bailly
Nicolas
N
Guilbaud
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D005434:Flow Cytometry; D005453:Fluorescence; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D011034:Podophyllotoxin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D011073:Polyamines / Q000378:metabolism*; D013096:Spermine / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; C534191:F14512; D011073:Polyamines; D013096:Spermine; D011034:Podophyllotoxin